EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye "EAGLE"


Phase 3 Results N/A

Eligibility Criteria

Inclusion Criteria

- Subtotal central retinal artery occlusion or central retinal artery occlusion with choroidal hypoperfusion not lasting longer than 20h
- Patients aged from 18 years to 75 years (in case of pre-existing blindness of other eye also older than 75 years)
- Informed consent of the patient

Exclusion Criteria

- Central retinal artery occlusion lasting longer than 20h
- Eye diseases, namely branch retinal artery occlusion, cilioretinal arteries supplying the macula, combined arterial-venous occlusion, proliferative diabetic retinopathy and elevated intraocular pressure (over 30 mmHg)
- Systemic diseases, namely severe general diseases, systemic arterial hypertension (systolic pressure > 200 mmHg), despite medical therapy, acute systemic inflammation (erythrocyte sedimentation rate > 30 mm within the first hour/ C-reactive protein > 1,0 mg/dl), antithrombin-III deficiency in case of thrombocytopenia (< 100000 per ml): pathologic clotting time, acute pancreatitis with elevated pancreas enzymes
- Medical History: heart attack within the last 6 weeks, intracerebral bleeding or neurosurgical operation within the last 4 weeks, therapy with marcumar/warfarin, allergic reaction to contrast agent, haemorrhagic diathesis, aneurysms, inflammatory vascular diseases (e.g., giant cell arteritis, Wegener´s granulomatosis), endocarditis, gastric ulcer
- Patient participation in other studies during the prior 4 weeks
- No willingness and ability of the patient to participate in all follow-up examinations
- Pregnancy
- Written consent not given
- Patient is not mobile (bedridden)
- Other conditions/ circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, no fixed abode)